Nurix Therapeutics (NRIX) Change in Cash (2019 - 2026)

Nurix Therapeutics (NRIX) has 8 years of Change in Cash data on file, last reported at -$175.8 million in Q1 2026.

• Change in Cash for Q1 2026 came in at -$175.8 million, down 415.73% year-over-year; the trailing twelve-month figure through Feb 2026 was -$4.7 million (down 117.83% YoY), and the FY2025 annual result was $137.0 million, up 147.48% from the prior year.
• Change in Cash declined to -$175.8 million in Q1 2026 per NRIX's latest filing, from $168.5 million in the prior quarter.
• Over five years, Change in Cash peaked at $168.5 million in Q4 2025 and troughed at -$175.8 million in Q1 2026.
• A 5-year average of -$507588.2 and a median of -$1.1 million in 2022 frame the typical range for Change in Cash.
• The sharpest annual moves came in 2023 and 2025: Change in Cash tumbled 2681.55% in 2023, then soared 1438.59% in 2025.
• A 5-year view of Change in Cash shows it stood at $16.9 million in 2022, then slipped by 27.16% to $12.3 million in 2023, then retreated by 11.12% to $11.0 million in 2024, then soared by 1438.59% to $168.5 million in 2025, then plunged by 204.3% to -$175.8 million in 2026.
• Business Quant data shows NRIX's Change in Cash at -$175.8 million in Q1 2026, $168.5 million in Q4 2025, and -$5.8 million in Q3 2025.